Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9602503 | 0.77 | CYP2A6 (0.54) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL5962350 | 0.74 | CYP2A6 (0.58) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL19760753 | 0.71 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL20912808 | 0.71 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL6637521 | 0.71 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL5540703 | 0.71 | CYP2A6 (0.55) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL3459782 | 0.71 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL30905568 | 0.71 | CYP2A6 (0.59) | CYP2A6ADRB2ASIC3LOXL2AGXT | |
| SCHEMBL18331458 | 0.70 | CYP2A6 (0.44) | CYP2A6OPRK1 | |
| SCHEMBL20912820 | 0.70 | CASR (0.45) | LOXL2CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385060-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-06-21 | — | — | US | disclosed |
| EP-3312184-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016202161-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385060-B2 | Piperidine derivative and preparation method and pharmaceutical use thereof | GPER1, CYP19A1, PGR | CYP2A6 65/4885ADRB2 158/4885ASIC3 2712/4885 |
| US-20180170943-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | GPER1, CYP19A1, PGR | CYP2A6 65/4885ADRB2 158/4885ASIC3 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.